Introduction：Basic information about CAS 674289-55-5|(S)-(-)-Blebbistatin, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | (S)-(-)-Blebbistatin |
|---|
| CAS Number | 674289-55-5 | Molecular Weight | 292.332 |
|---|
| Density | 1.3±0.1 g/cm3 | Boiling Point | 507.3±60.0 °C at 760 mmHg |
|---|
| Molecular Formula | C18H16N2O2 | Melting Point | 210-212ºC |
|---|
| MSDS | / | Flash Point | 260.6±32.9 °C |
|---|
Names
| Name | blebbistatin |
|---|
| Synonym | More Synonyms |
|---|
(S)-(-)-Blebbistatin BiologicalActivity
| Description | Blebbistatin is a selective non-muscle myosin II (NMII) inhibitor, promotes directional migration of corneal endothelial cells (CECs) and accelerates wound healing, and better preserves cell junctional integrity and barrier function[1]. |
|---|
| Related Catalog | Signaling Pathways >>Cytoskeleton >>MyosinResearch Areas >>Others |
|---|
| Target | Non-muscle myosin II (NMII)[1] |
|---|
| In Vitro | The therapeutic potential of targeting NMII to enhance CEC migration is investigated using bovine corneal endothelial cells (BCECs). Blebbistatin, a direct myosin motor inhibitor, promotes migration and directional persistence in CECs through decreasing actin retrograde flow and increasing lamellipodial protrusion persistence to accelerate wound healing in vitro[1]. |
|---|
| In Vivo | Blebbistatin (0.05 mL, 20 μM; intracameral injection; daily; for 6 days; New Zealand white rabbits) treatment promotes wound healing in rabbit corneal endothelial scraping model[1]. Animal Model: New Zealand white rabbits (16-20 weeks; 3-3.5 kg) with injected xylazine 5 mg/kg and ketamine 40 mg/kg[1] Dosage: 0.05 mL; 20 μM Administration: Intracameral injection; daily; for 6 days Result: Resulted in significant improvement of corneal clarity and corneal edema resolution, implying the restoration of an intact corneal endothelial monolayer. |
|---|
| References | [1]. Ho WT, et al. Targeting non-muscle myosin II promotes corneal endothelial migration through regulating lamellipodial dynamics. J Mol Med (Berl). 2019 Sep;97(9):1345-1357. |
|---|
Chemical & Physical Properties
| Density | 1.3±0.1 g/cm3 |
|---|
| Boiling Point | 507.3±60.0 °C at 760 mmHg |
|---|
| Melting Point | 210-212ºC |
|---|
| Molecular Formula | C18H16N2O2 |
|---|
| Molecular Weight | 292.332 |
|---|
| Flash Point | 260.6±32.9 °C |
|---|
| Exact Mass | 292.121185 |
|---|
| PSA | 52.90000 |
|---|
| LogP | 1.62 |
|---|
| Vapour Pressure | 0.0±1.4 mmHg at 25°C |
|---|
| Index of Refraction | 1.681 |
|---|
| InChIKey | LZAXPYOBKSJSEX-UHFFFAOYSA-N |
|---|
| SMILES | Cc1ccc2c(c1)C(=O)C1(O)CCN(c3ccccc3)C1=N2 |
|---|
Safety Information
| Hazard Codes | Xn |
|---|
| Risk Phrases | R20/21/22 |
|---|
| Safety Phrases | 26-36/37 |
|---|
Synonyms
| (−)-Blebbistatin |
| (+/-)-Blebbistatin |
| (3aS)-3a-Hydroxy-6-methyl-1-phenyl-1,2,3,3a-tetrahydro-4H-pyrrolo[2,3-b]quinolin-4-one |
| Blebbistatin |
| 4H-Pyrrolo[2,3-b]quinolin-4-one, 1,2,3,3a-tetrahydro-3a-hydroxy-6-methyl-1-phenyl-, (3aS)- |
| (S)-Blebbistatin |
| 3a-hydroxy-6-methyl-1-phenyl-2,3-dihydropyrrolo[2,3-b]quinolin-4-one |
